Cargando…

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease

Detalles Bibliográficos
Autores principales:	Olie, Renske H., van der Meijden, Paola E. J., Spronk, Henri M. H., van Oerle, Rene, Barvik, Stale, Bonarjee, Vernon V. S., ten Cate, Hugo, Nilsen, Dennis W. T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697509/ https://www.ncbi.nlm.nih.gov/pubmed/31428739 http://dx.doi.org/10.1055/s-0039-1695710

Ejemplares similares

The coagulation system in atherothrombosis: Implications for new therapeutic strategies
por: Olie, Renske H., et al.
Publicado: (2018)

Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding
por: van der Meijden, Paola E. J., et al.
Publicado: (2013)

The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease
por: Nilsen, Dennis W. T., et al.
Publicado: (2022)

Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes
por: Sommeijer, Dirkje W, et al.
Publicado: (2005)

Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability
por: van de Berg, Tom W., et al.
Publicado: (2021)

Blood coagulation and the risk of atherothrombosis: a complex relationship
por: Spronk, Henri MH, et al.
Publicado: (2004)

Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
por: Henskens, Yvonne M. C., et al.
Publicado: (2018)

The activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-elevation myocardial infarction: a brief communication
por: Brügger-Andersen, Trygve, et al.
Publicado: (2010)

Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice
por: Posthuma, Jelle J., et al.
Publicado: (2019)

Thrombin Generation Capacity of Prothrombin Complex Concentrate in an In Vitro Dilutional Model
por: Grottke, Oliver, et al.
Publicado: (2013)

Integrating platelet and coagulation activation in fibrin clot formation
por: Swieringa, Frauke, et al.
Publicado: (2018)

Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1
por: De Simone, Ilaria, et al.
Publicado: (2022)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Relationships between coagulation factors and thrombin generation in a general population with arterial and venous disease background
por: van Paridon, Pauline C. S., et al.
Publicado: (2022)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Evaluation of the analytical performance of the PC100 platelet counter
por: Nagy, Magdolna, et al.
Publicado: (2021)

ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
por: Willems, Loes H., et al.
Publicado: (2021)

Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events
por: Loeffen, Rinske, et al.
Publicado: (2016)

Thrombin Generation in the Glasgow Myocardial Infarction Study
por: Smid, Machiel, et al.
Publicado: (2013)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

The hypercoagulable profile of patients with stent thrombosis
por: Loeffen, R, et al.
Publicado: (2015)

Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation
por: Brouns, Sanne L. N., et al.
Publicado: (2020)

Effects of Fibrinogen Concentrate on Thrombin Generation, Thromboelastometry Parameters, and Laboratory Coagulation Testing in a 24-Hour Porcine Trauma Model
por: Zentai, Christian, et al.
Publicado: (2015)

Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease
por: Kremers, Bram M. M., et al.
Publicado: (2019)

Thrombin generation by calibrated automated thrombography in goat plasma: Optimization of an assay
por: D'Alessandro, Elisa, et al.
Publicado: (2021)

Calibrated automated thrombogram II: removing barriers for thrombin generation measurements
por: Giesen, P. L. A., et al.
Publicado: (2021)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

A new method to determine tissue specific tissue factor thrombomodulin activities: endotoxin and particulate air pollution induced disbalance
por: Frederix, Kim, et al.
Publicado: (2008)

Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention
por: Hulshof, Anne-Marije, et al.
Publicado: (2021)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort
por: Mulder, Mark M. G., et al.
Publicado: (2021)

Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy
por: de Breet, C. P. D. M., et al.
Publicado: (2021)

Integrating Mechanisms in Thrombotic Peripheral Arterial Disease
por: Nagy, Magdolna, et al.
Publicado: (2022)

Coagulation Factor Xa Induces Proinflammatory Responses in Cardiac Fibroblasts via Activation of Protease-Activated Receptor-1
por: D’Alessandro, Elisa, et al.
Publicado: (2021)

Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity
por: Kuiper, Gerhardus J. A. J. M., et al.
Publicado: (2016)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i4hc8reb33smsosidtov2k0cnf